Peptides for Immune Support
Research overview of peptides studied for immune function and immunomodulation. Thymosin alpha-1, thymulin, LL-37, and immune peptide evidence.
Research Overview
Immune peptide research includes thymic peptides (thymosin alpha-1, thymulin), antimicrobial peptides (LL-37, defensins), and bioregulators targeting immune function. Several immune peptides have regulatory approval in various countries for specific indications.
Thymosin alpha-1 is among the most studied immune peptides, with approvals in numerous countries for hepatitis B/C treatment and as cancer therapy adjuvant. Its immunomodulatory properties have been documented in multiple clinical trials, though applications beyond approved indications are less supported.
Antimicrobial peptides represent the innate immune system's first line of defense and are being studied for their immunomodulatory properties beyond direct pathogen killing. This research area is evolving rapidly with potential implications for infection control and immune regulation.
Key Immune Peptides
Thymosin Alpha-1 (Tα1)
Status: Approved in 35+ countries
| Indication | Evidence Level |
|---|---|
| Hepatitis B/C | Moderate-High |
| Cancer adjuvant | Moderate |
| Immune deficiency | Moderate |
| General immune support | Low |
The most clinically validated immune peptide with multiple approved indications.
Thymulin
| Aspect | Details |
|---|---|
| Origin | Thymic hormone |
| Mechanism | T-cell modulation |
| Evidence | Low-Moderate |
| Clinical use | Research stage |
LL-37 (Cathelicidin)
| Function | Evidence Level |
|---|---|
| Antimicrobial | Well-established |
| Immunomodulation | Moderate |
| Therapeutic use | Research stage |
Endogenous antimicrobial peptide with documented immune effects.
Thymic Bioregulators
| Peptide | Research Status |
|---|---|
| Thymalin | Approved in Russia |
| Thymogen | Approved in Russia |
| Vilon | Research stage |
Russian-developed thymic peptides with varying evidence quality.
Antimicrobial Peptides (AMPs)
| Peptide Class | Immune Function |
|---|---|
| Defensins | Innate immunity |
| Cathelicidins | Broad antimicrobial |
| Lactoferricin | Immune modulation |
Evidence Hierarchy
- Best supported: Thymosin alpha-1 (approved indications)
- Moderate support: LL-37 (characterization, mechanism)
- Limited support: Thymulin, thymic bioregulators
- Research stage: Most AMPs for immune modulation
Research Considerations
- “Immune support” is a broad, often vague claim
- Approved indications differ from general immune enhancement
- Many claims extrapolate from in vitro studies
- Bioregulator literature requires careful evaluation
Peptides Studied for Immune Support
Selank
ModerateA synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed by Russian researchers and approved in Russia since 2009 for anxiety and neurasthenia. Demonstrates anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence liability. Extensive Russian clinical research supports efficacy, though Western independent replication remains limited.
Kristagen
LowA synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Vilon
LowA synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework. Claimed to support thymus gland function and immune modulation. No Western clinical validation exists; all research originates from Russian institutes.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.